Clinical Data Presentations at AAT in Alzheimer`s Disease
(WorldNews Germany)

March 14, 2018 / 7:30 am, CET Planegg/Munich, Germany, March 14, 2018 Clinical Data Presentations at AAT in Alzheimer`s Disease Support Investigating Gantenerumab in Higher Doses in New Pivotal Phase 3 Trials - Three abstracts will be presented at the upcoming Alzheimer`s and Parkinson`s Disease conference AAT-AD/PDTM Focus Meeting 2018, thereof one as Late Breaking Abstract. - Gantenerumab showed greater and consistent amyloid beta reduction in the brain after one year of treatment at higher doses in open label extension (OLE) clinical studies in patients with prodromal to mild Alzheimer`s disease compared to lower dosing. - Results from clinical OLE trials supported higher dosing up to...